Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: Meta-analysis of randomized controlled trials

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Peedikayil, Musthafa Chalikandy ^a   AlSohaibani, Fahad Ibrahim ^a   Alkhenizan, Abdullah Hamad ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; OMEPRAZOLE;

ANOREXIA; ARTICLE; BACTERIAL CLEARANCE; COMPARATIVE EFFECTIVENESS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; META ANALYSIS; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; TASTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84904034815     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085620     Document Type: Article

References (41)

1. Correa P (1997) Helicobacter pylori as a pathogen and carcinogen. J Physiol Pharmacol 48 Suppl 4:19-24.
2. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon ATR, et al (2012) Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 61:646-64.
3. Bayerdorffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, et al (1995) Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 345:1591-4.
4. Jafri NS, Hornung CA, Howden CW (2008) Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 148:923-31. (Pubitemid 351860824)
5. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, et al (1997) Current European concepts in the management of Helicobacter pylori infection-the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 9:1-2. (Pubitemid 27047348)
6. Karczewska E, Wojtas-Bonior I, Sito E, Zwolinska-Wcislo M, Budak A (2011) Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland. Pharmacol Rep 63:799-807.
7. Li Y, Huang X, Yao L, Shi R, Zhang G (2010) Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 122:413-22.
8. Cuadrado-Lavin A, Salcines-Caviedes JR, Carrascosa MF, Dierssen-Sotos T, Cobo M, et al (2012) Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial. J Antimicrob Chemother 67:2254-9.
9. Hung IF, Chan P, Leung S, Chan FS, Hsu A, et al (2009) Clarithromycin-amoxycillin- containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong? Helicobacter 14:505-11.
10. Molina-Infante J, Gisbert JP (2011) Levofloxacin in first-line eradication regimens for Helicobacter pylori: better test antibiotic susceptibility before treating. Gut 60:1605; author reply -6.
11. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre G, et al (2010) Clinical trial: clarithromycin vs. levofloxacin in firstline triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 31:1077-84.
12. Iacopini F, Crispino P, Paoluzi OA, Consolazio A, Pica R, et al (2005) One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis 37:571-6. (Pubitemid 44356069)
13. Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M (2010) Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study. Eur J Intern Med 21:310-4.
14. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, et al (2011) A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 106:1970-5.
15. Chen LW, Chien RN, Chang JJ, Fang KM, Chang LC (2010) Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study. Int J Clin Pract 64:1530-4.
16. Cheng H, Hu FL, Zhang GX, Shi RH, Du YQ, et al (2010) [Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: a multicentral, randomized, controlled clinical study]. Zhonghua Yi Xue Za Zhi 90:79-82.
17. Choi KH, Chung WC, Lee KM, Paik CN, Kim EJ, et al (2011) Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 26:785-90.
18. Liou JM, Lin JT, Chang CY, Chen MJ, Cheng TY, et al (2010) Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 59:572-8.
19. Nista EC, Candelli M, Zocco MA, et al (2006) Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 101:1985-90. (Pubitemid 44337620)
20. Rispo A, Di Girolamo E, Cozzolino A, Bozzi R, Morante A, et al (2007) Levofloxacin in first-line treatment of Helicobacter pylori infection. Helicobacter 12:364-5. (Pubitemid 47196341)
21. Zullo A, De Francesco V, Scaccianoce G, Manes G, Efrati C, et al (2007) Helicobacter pylori eradication with either quadruple regimen with lactoferrin or levofloxacin-based triple therapy: a multicentre study. Dig Liver Dis 39:806-10. (Pubitemid 47215580)
22. Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, et al (2000) Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 14:1339-43.
23. Di Caro S, Zocco MA, Cremonini F, et al (2002) Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 14:1309-12. (Pubitemid 36054918)
24. Antos D, Schneider-Brachert W, Bastlein E, et al (2006) 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 11:39-45.
25. Castro-Fernandez M, Lamas E, Perez-Pastor A, et al (2009) Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori. Rev Esp Enferm Dig 101:395-8, 9-402.
26. Schrauwen RW, Janssen MJ, de Boer WA (2009) Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication. Neth J Med 67:96-101.
27. Zhang ZF, Zhao G, Liu LN (2008) [Effectiveness and safety of proton pump inhibitor and levofloxacin based first-line triple therapy in the eradication of Helicobacter pylori: a meta-analysis]. Zhonghua Yi Xue Za Zhi 88:2722-5.
28. Chey WD, Wong BC (2007) American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102:1808-25. (Pubitemid 47206706)
29. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, et al (2009) Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 24:1587-600.
30. Gisbert JP, Morena F (2006) Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 23:35-44. (Pubitemid 43381164)
31. Saad RJ, Schoenfeld P, Kim HM, Chey WD (2006) Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 101:488-96. (Pubitemid 46894012)
32. Goh KL, Navaratnam P (2011) High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter 16:241-5.
33. Liao J, Zheng Q, Liang X, Zhang W, Sun Q, et al (2013) Effect of Fluoroquinolone Resistance on 14-day Levofloxacin Triple and Triple Plus Bismuth Quadruple Therapy. Helicobacter 18(5):373-7.
34. O'Connor A, Taneike I, Nami A, Fitzgerald N, Ryan B, et al (2013) Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Ir J Med Sci 182(4):693-5.
35. Talebi Bezmin Abadi A, Ghasemzadeh A, Taghvaei T, Mobarez AM (2012) Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran. Intern Emerg Med 7:447-52.
36. Zullo A, Perna F, Hassan C, Ricci C, Saracino I, et al (2007) Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 25:1429-34. (Pubitemid 46848887)
37. Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, et al (2009) Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 24:1230-5.
38. Perna F, Zullo A, Ricci C, Hassan C, Morini S, et al (2007) Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 39:1001-5. (Pubitemid 350018698)
39. Carothers JJ, Bruce MG, Hennessy TW, et al (2007) The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 44:e5-8.
40. Gisbert JP, Pajares R, Pajares JM (2007) Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter 12 Suppl 2:50-8. (Pubitemid 350076232)
41. Gisbert JP, Perez-Aisa A, Castro-Fernandez M, Barrio J, Rodrigo L, et al (2010) Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. Dig Liver Dis 42:287-90.